Finally, it is decided! The European medicines Agency (EMA) will relocate to Amsterdam following UK’s withdrawal from the European Union. The decision followed an assessment of the bids by the European Commission and EMA. By 30 March 2019 at the latest, EMA should be in operation in Amsterdam.

EMA’s relocation will also impact the continuous supply of medicines for human and veterinary use within the European Union. Marketing authorisation holders, applicants and sponsors of centrally authorised medicines should consider which changes have to be addressed before the United Kingdom leaves the European Union. Necessary changes should be made by 30 March 2019 at the latest. To help pharmaceutical companies prepare for Brexit, EMA has published a procedural guidance and a Questions & Answers document.

Share This